Fundraising FoxQuanta Therapeutics
South San Francisco, US · 11 known investors
Find your way into Quanta Therapeutics
Sign up to see every warm intro you have to Quanta Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Quanta Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers. Its pipeline includes clinical and preclinical candidates aimed at KRAS mutations (including G12D and G12V) beyond those addressed by approved G12C inhibitors, alongside a RAS-partner discovery program using conformation-sensitive assays.
Founders & leadership
Board
Investors · 11
How we know: Finchley Healthcare Ventures's portfolio page · Not right? Tell us
How we know: Longitude Capital's portfolio page · biospace.com · the VCSheet dataset · Not right? Tell us
How we know: Sofinnova Ventures's portfolio page · a partner's Signal profile · board seat on SEC Form D · biospace.com · Not right? Tell us
How we know: Vida Ventures's portfolio page · a partner's Signal profile · funding news · biospace.com · the VCSheet dataset · Not right? Tell us
Also in the syndicate · 5
Funding
SEC filings, press & company announcements$146.3M disclosed across 3 of 4 rounds · 2021–2023
- Undisclosed amountSeries DMay 2023 · 3 sources
Avidity Partners (lead), AbbVie Ventures, BVF Partners, GC&H Investments (the partner fund of Cooley LLP), Longitude Capital, Sofinnova Investments, Surveyor Capital (a Citadel company), Vida Ventures, WS Investment Company (Wilson Sonsini’s venture arm)
Source ↗
▶$76.2MraisedJun 2026 · 17 investors · BiotechnologyRule 506(b)
- Maha KatabiDirector
- Perry NisenExecutive Officer, Director
- Cameron PittExecutive Officer, Director
- Maria FardisDirector
- Ying HuangDirector
- Derek MetzgerExecutive Officer
- Rajul JainDirector
- Offering amount
- $89.1M
- Amount sold
- $76.2M
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedFeb 2023 · 9 investors · BiotechnologyRule 506(b)
- Arjun GoyalDirector
- Cameron PittExecutive Officer, Director
- Ying HuangDirector
- Perry NisenExecutive Officer, Director
- Samuel SaksDirector
- Leonardo FaoroExecutive Officer
- Maria FardisDirector
- Maha KatabiDirector
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$40.2MraisedNov 2021 · 10 investors · BiotechnologyRule 506(b)
- Cameron PittDirector
- Maha KatabiDirector
- Perry NisenExecutive Officer, Director
- Maria FardisDirector
- Samuel SaksDirector
- Arjun GoyalDirector
- Offering amount
- $70.2M
- Amount sold
- $40.2M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Quanta Therapeutics went on to found or lead other companies.
Related companies · 3
Companies working in the same space as Quanta Therapeutics.
In the news
Frequently asked questions
- What does Quanta Therapeutics do?
- Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers. Its pipeline includes clinical and preclinical candidates aimed at KRAS mutations (including G12D and G12V) beyond those addressed by approved G12C inhibitors, alongside a RAS-partner discovery program using conformation-sensitive assays.
- Who are Quanta Therapeutics's investors?
- Quanta Therapeutics's investors include Finchley Healthcare Ventures, Longitude Capital, Sofinnova Ventures, Vida Ventures, Biotechnology Value Fund, Frazier Life Sciences.
- How much funding has Quanta Therapeutics raised?
- Quanta Therapeutics has disclosed $146.3M raised across 3 of its 4 known rounds.
- Where is Quanta Therapeutics headquartered?
- Quanta Therapeutics is headquartered in South San Francisco, US.